Drugs Made In America Acquisition II Corp. (DMII): debt financing — DMIIU enters $1.4M convertible note agreement for de-SPAC financing; issues $300K interim note

Drugs Made In America Acquisition II Corp.

Total financing commitment of $1.4M; $150K already received, $300K funded on March 30, 2026 as interim convertible note.
Conversion at 35% discount to post-merger market value at investor's discretion; nine-month maturity.
Proceeds used for audit, accounting, SEC, Nasdaq fees, legal costs, and transaction preparation.
Existing sponsor non-performing; investor has right to acquire sponsor interests when legally permitted.
Exclusivity period of six months to complete de-SPAC transaction.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Drugs Made In America Acquisition II Corp. incurred convertible notes of $300,000 with Alpha Multi Family Office at does not bear interest maturing nine months from the date of issuance.

Instrument: convertible notes
Principal: $300,000
Counterparty: Alpha Multi Family Office
Rate: does not bear interest
Maturity: nine months from the date of issuance
Event: incurrence

Exact text from the filing

In addition, on March 30, 2026, the Company and the Investor entered into an Interim Convertible Note in the amount of $300,000 (the “ Second Note ”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Drugs Made In America Acquisition II Corp. entered into Interim Convertible Note with Alpha Multi Family Office valued at $300,000 Interim Convertible Note, convertible with 35% discount (effective 2026-03-30).

Action: entry
Counterparty: Alpha Multi Family Office
Value: $300,000 Interim Convertible Note, convertible with 35% discount
Effective: 2026-03-30

Exact text from the filing

on March 30, 2026, the Company and the Investor entered into an Interim Convertible Note in the amount of $300,000 (the " Second Note ").

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Drugs Made In America Acquisition II Corp. entered into Definitive Investment and Sponsor Transition Agreement with Alpha Multi Family Office valued at $1,400,000 Convertible Notes Financing (effective 2026-03-24).

Action: entry
Agreement: notes offering
Counterparty: Alpha Multi Family Office
Value: $1,400,000 Convertible Notes Financing
Effective: 2026-03-24

Exact text from the filing

Effective March 24, 2026, the Company and the Investor entered into the Definitive Investment and Sponsor Transition Agreement (the " Agreement ") for the Convertible Notes Financing, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

View on SEC.gov

7 debt financings filed in the last 30 days. Browse all debt financings →

Drugs Made In America Acquisition II Corp. filing history →

Source: SEC EDGAR

accession 0001213900-26-039986

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.